(February 23, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced the start of enrollment in the world's largest drug-eluting stent registry. The TAXUS OLYMPIC registry plans to enroll more than 30,000 patients at more than 600 centers in the United States, Europe and other international locations. The registry is designed to collect and analyze "real-world" clinical outcomes data for the TAXUS® Liberté™ paclitaxel-eluting stent system in the treatment of patients with coronary artery disease. (A registry enlists large numbers of clinicians to document the performance of a specific therapy for a particular disease or condition.)

The OLYMPIC registry will enroll patients in five phases, corresponding to the commercial introduction of the TAXUS Liberté system in different regions of the world. The initial, transitional phase is enrolling patients from a limited number of international markets in which Boston Scientific launched the TAXUS Liberté system in January. This phase will be followed by enrollment of patients from a broader number of international markets, then from European markets and finally from a two-phase U.S. enrollment.

Waqar H. Ahmed, M.D., M.S., FACC, at King Fahed Armed Forces Hospital in Jeddah, Saudi Arabia enrolled the first patient in the OLYMPIC registry last week. Other physicians are scheduled to begin enrolling patients immediately. The first phase of the OLYMPIC registry will enroll 500 patients.

"We are excited to have the TAXUS Liberté stent system available to treat our patients," said Dr. Ahmed. "It is a significant advance in stent design and deliverability, and it will add important data to the growing catalog of clinical information on drug-eluting stents."

"As the first real-world study of our next-generation TAXUS Liberté stent system, the OLYMPIC registry is an important step in our drug-eluting stent program," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "Its unprecedented size demonstrates our ongoing commitment to leadership and innovation in this field."

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with clinical trials, the regulatory approval process, commercialization of new technologies, litigation, intellectual property, and other factors described in the Company's filings with the Securities and Exchange Commission.